CLINICAL TRIALS PROFILE FOR IMATINIB MESYLATE
✉ Email this page to a colleague
All Clinical Trials for Imatinib Mesylate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002514 ↗ | Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission | Completed | Medical Research Council | Phase 3 | 1993-04-01 | RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission. |
| NCT00002514 ↗ | Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission | Completed | National Cancer Institute (NCI) | Phase 3 | 1993-04-01 | RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission. |
| NCT00002514 ↗ | Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission | Completed | Eastern Cooperative Oncology Group | Phase 3 | 1993-04-01 | RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission. |
| NCT00004932 ↗ | STI571 in Treating Patients With Recurrent Leukemia | Completed | National Cancer Institute (NCI) | Phase 1 | 2002-01-01 | RATIONALE: Imatinib mesylate may interfere with the growth of cancer cells and may be an effective treatment for leukemia. PURPOSE: Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent leukemia. |
| NCT00004932 ↗ | STI571 in Treating Patients With Recurrent Leukemia | Completed | Children's Oncology Group | Phase 1 | 2002-01-01 | RATIONALE: Imatinib mesylate may interfere with the growth of cancer cells and may be an effective treatment for leukemia. PURPOSE: Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent leukemia. |
| NCT00006052 ↗ | STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia | Completed | Novartis | Phase 2 | 2000-06-01 | RATIONALE: STI571 may interfere with the growth of cancer cells and may be effective treatment for chronic myelogenous leukemia. PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have accelerated phase chronic myelogenous leukemia. |
| NCT00006053 ↗ | STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa | Completed | Novartis | Phase 2 | 2000-06-01 | RATIONALE: STI571 may interfere with the growth of cancer cells and may be effective treatment for chronic myelogenous leukemia. PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have chronic myeloid leukemia that has not responded to interferon alfa. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Imatinib Mesylate
Condition Name
Clinical Trial Locations for Imatinib Mesylate
Trials by Country
Clinical Trial Progress for Imatinib Mesylate
Clinical Trial Phase
Clinical Trial Sponsors for Imatinib Mesylate
Sponsor Name
